Amphastar Pharmaceuticals, Inc. (AMPH) — 8-K Filings

8-K Filings (13)

• Amphastar Pharmaceuticals Enters Material Definitive Agreement — Oct 24, 2025 Risk: medium
  On October 21, 2025, Amphastar Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agree
• Amphastar Pharmaceuticals Enters Material Definitive Agreement — Sep 18, 2025 Risk: medium
  On September 15, 2025, Amphastar Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agre
• Amphastar Pharmaceuticals Enters Material Definitive Agreement — Aug 12, 2025 Risk: medium
  Amphastar Pharmaceuticals, Inc. announced on August 8, 2025, that it has entered into a Material Definitive Agreement. The filing also includes Regulation FD Di
• Amphastar Pharmaceuticals Announces Board and Compensation Changes — Jul 21, 2025 Risk: low
  Amphastar Pharmaceuticals, Inc. announced on July 18, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the
• Amphastar Pharmaceuticals Files 8-K on Corporate Matters — Jun 4, 2025 Risk: low
  On June 2, 2025, Amphastar Pharmaceuticals, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws, submission of matters to a
• Amphastar Pharmaceuticals Files 8-K — May 7, 2025 Risk: low
  On May 7, 2025, Amphastar Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Amphastar Pharmaceuticals Files 8-K on Financials — Feb 27, 2025 Risk: low
  Amphastar Pharmaceuticals, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition, as well as filing financial s
• Amphastar Pharmaceuticals Files 8-K on Financials — Nov 6, 2024 Risk: low
  Amphastar Pharmaceuticals, Inc. filed an 8-K on November 6, 2024, to report on its results of operations and financial condition, as well as to file financial s
• Amphastar Pharma Secures $150M Loan Facility — Aug 30, 2024 Risk: medium
  On August 28, 2024, Amphastar Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a Loan and Security Agreement with an affiliate o
• Amphastar Pharmaceuticals Files 8-K on Financials — Aug 7, 2024 Risk: low
  Amphastar Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, to report on its results of operations and financial condition, and to file financial statements
• Amphastar Pharmaceuticals Appoints New CFO — Jun 4, 2024 Risk: medium
  Amphastar Pharmaceuticals, Inc. announced on June 3, 2024, the appointment of Robert J. Lerman as Chief Financial Officer, effective immediately. Lerman previou
• Amphastar Pharmaceuticals Files 8-K — May 8, 2024 Risk: low
  On May 8, 2024, Amphastar Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Amphastar Pharma Files 8-K on Financial Condition — Feb 28, 2024 Risk: low
  Amphastar Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing, under SEC File Nu

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX